About
Gene Therapy
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyBoston & New England
Clinical Trials (14)
View allTotal Trials
14
As Lead Sponsor
13
As Collaborator
1
Total Enrollment
411
By Phase
PHASE2: 4PHASE2/PHASE3: 1PHASE1/PHASE2: 5PHASE1: 1
By Status
COMPLETED: 7ACTIVE_NOT_RECRUITING: 5RECRUITING: 1ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline14 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07174726Lead Sponsor
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
PHASE2Recruiting
10 participants
Started: Sep 10, 2025 · Completed: Dec 15, 2030
NCT04850118Lead Sponsor
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
PHASE2/PHASE3Active, not recruiting
85 participants
Started: Mar 14, 2024 · Completed: Oct 31, 2029
NCT06275620Lead Sponsor
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
PHASE2Enrolling by invitation
24 participants
Started: Nov 14, 2023 · Completed: Dec 31, 2029
NCT06333249Lead Sponsor
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
PHASE2Active, not recruiting
14 participants
Started: Apr 13, 2021 · Completed: Feb 28, 2027
NCT03316560Lead Sponsor
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
PHASE1/PHASE2Active, not recruiting
29 participants
Started: Apr 16, 2018 · Completed: Mar 31, 2025
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...